Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection

[1]  Y. Suzuki,et al.  Long‐term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide‐naïve chronic hepatitis B patients , 2014, Journal of viral hepatitis.

[2]  A. Lok,et al.  Management of hepatitis B: our practice and how it relates to the guidelines. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  S. Zeuzem,et al.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2014, Journal of hepatology.

[4]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[5]  Yoshiyuki Suzuki,et al.  Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study , 2013, Journal of Gastroenterology.

[6]  C. Perry,et al.  Peginterferon-α-2a (40kD) , 2012, Drugs.

[7]  Yoshiyuki Suzuki,et al.  Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. , 2012, Journal of hepatology.

[8]  A. Uitterlinden,et al.  Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. , 2012, Gastroenterology.

[9]  Yoshiyuki Suzuki,et al.  Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan , 2012, Journal of Gastroenterology.

[10]  N. Hayashi,et al.  Efficacy and safety of treatment with peginterferon alfa-2a for chronic hepatitis B patients , 2012 .

[11]  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.

[12]  P. Marcellin,et al.  Shorter durations and lower doses of peginterferon alfa‐2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C , 2011, Hepatology.

[13]  Ching-Lung Lai,et al.  Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B , 2010, Hepatology.

[14]  R. D. de Man,et al.  Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside‐naïve HBeAg‐positive patients with chronic hepatitis B * , 2010, Journal of viral hepatitis.

[15]  E. Steyerberg,et al.  Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. , 2009, Gastroenterology.

[16]  B. McMahon,et al.  Chronic hepatitis B: Update 2009 , 2009, Hepatology.

[17]  P. Marcellin,et al.  Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. , 2009, Gastroenterology.

[18]  K. Tadokoro,et al.  Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes. , 2006, Journal of virological methods.

[19]  P. Marcellin,et al.  Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B , 2006, Gut.

[20]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[21]  Yao Guang.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B in China , 2005 .

[22]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[23]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[24]  B. McMahon,et al.  [AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines]. , 2004, Romanian journal of gastroenterology.

[25]  Ching-Lung Lai,et al.  Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.

[26]  Yoshiyuki Suzuki,et al.  Efficacy of Lamivudine Therapy and Factors Associated with Emergence of Resistance in Chronic Hepatitis B Virus Infection in Japan , 2003, Intervirology.

[27]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[28]  Y. Liaw.  Results of lamivudine trials in Asia. , 2003, Journal of hepatology.

[29]  Yoshiyuki Suzuki,et al.  Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. , 2002, Journal of hepatology.

[30]  Yoshiyuki Suzuki,et al.  Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C , 2002, Journal of Gastroenterology.

[31]  S. Nair,et al.  Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? , 2001, Hepatology.

[32]  Zhi-xin Xu,et al.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.

[33]  C. Perry,et al.  Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. , 2001, Drugs.

[34]  H. Okamoto,et al.  Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. , 1999, Journal of virological methods.

[35]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[36]  E. Schiff,et al.  A preliminary trial of lamivudine for chronic hepatitis B infection. , 1995, The New England journal of medicine.

[37]  Lu-Yu Hwang,et al.  HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS A Prospective Study of 22 707 Men in Taiwan , 1981, The Lancet.

[38]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .